Skip to content
Medical Health Aged Care, Regional Country Services

New digital heart monitor prevents premature heart related deaths.

Numedico Technologies 2 mins read

Numedico Technologies and QT Medical Launch the Revolutionary PCA 500 Diagnostic ECG, Approved by FDA, TGA, and Medsafe, in Australia & New Zealand

 

Adelaide Australia and Los Angeles, California — Numedico Technologies and QT Medical are proud to announce the exclusive launch of the PCA 500 in Australia and New Zealand, the world's first digital, cloud based 12-lead resting heart stress test approved by the FDA, TGA, and Medsafe in Australia & New Zealand.

 

What sets the PCA 500 apart is its revolutionary design, digital connectivity devoid of leads, that allows individuals with no experience or training, including patients themselves, to complete a medical standard 12-lead equivalent heart stress test. The device's intuitive interface and precise diagnostic capabilities make, what used to be a complicated procedure of cardiac assessment, so simple and user-friendly that professional medical training is no longer a barrier. 

 

Neville Calvert, Founder & Managing Director of Numedico Technologies, explains, "The PCA 500 is not just an advancement; it’s a revolution in cardiac care. By making hospital standard 12-lead equivalent ECG test accessible to everyone, we are democratising healthcare and empowering individuals to take control of their heart health. In a first responder, hospital, or clinical environment the PCA500 reduces the time required to evaluate the patient’s heart state.”  

 

Dr. Ruey-Kang Chang, Founder & CEO of QT Medical, adds, "The FDA, TGA, and MedSafe approvals are a testament to the PCA 500's ground-breaking innovation. Its ease of use, accuracy, and efficiency are unparalleled, and we believe it will redefine cardiac care in Australia, New Zealand, and beyond."

 

Numedico Technologies, as the exclusive importer and distributor, is enthusiastic about introducing this state-of-the-art device to the region, affirming its commitment to enhancing healthcare through innovative technology.

 


About us:

Established in 2016 out of a desire to pursue optimal Medtech solutions and to challenge

the status quo in medical devices. Numedico is a globally focused safety medical devices manufacturer and distributor. A key priority for Numedico is safety and sustainability.

Our future focus is to improve healthcare and to find the best and safest

solutions to suit our customer’s needs. We are always exploring what’s

possible, continuously innovating, and seeking new solutions to suit evolving industry and

consumer needs.www.numedico.com

QT Medical, Inc. is a global leader in cardiac technology, committed to developing advanced ECG/EKG solutions that make quality cardiac care accessible to all. Through relentless innovation and a focus on simplicity and accuracy, QT Medical aims to revolutionize the way cardiac care is approached worldwide. For more information, please visit www.qtmedical.com


Contact details:

Numedico Technologies Pty Ltd

Nick Slaughter

[email protected]

+61 450 909 359

QT Medical, Inc.

Shirley Wang

[email protected]

+1 279 297 8691

Media

More from this category

  • Medical Health Aged Care
  • 21/01/2026
  • 06:10
Amoeba

Gold medal winner at SIVAL, Amoéba displays its ambitions for its biocontrol solution

Chassieu, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Chassieu (France), 20 January 2026 – 6:00 pm -Amoéba (FR0011051598 - ALMIB), industrial greentech specialised in the development of natural microbiological solutions based on the patented use of amoebae, recaps its recent participation in SIVAL (International Exhibition of Plant Production Techniques) in Angers (France). During this leading European and global event for the crop industry, Amoéba won the gold medal in the SIVAL Innovation 2026 Competition for its biocontrol solution and announced, together with its partner Koppert, the commercial launch in 2026 of its biocontrol solution for treating vineyards and vegetable crops as…

  • Medical Health Aged Care
  • 21/01/2026
  • 00:41
Crown Bioscience

Crown Bioscience San Diego Laboratory Achieves CAP Accreditation, Building on CLIA Certification to Expand Clinical-Grade Capabilities

SAN DIEGO–BUSINESS WIRE– Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announced that its San Diego laboratory…

  • Contains:
  • Medical Health Aged Care
  • 20/01/2026
  • 10:00
Monash University

Monash University researcher appointed to the board of the Asthma Council

The National Asthma Council Australia (NAC) has announced the appointment of Pharmaceutical Society of Australia (PSA) nominee Dr Amanda Cross to the board. Dr Cross is a clinical pharmacist and Senior Research Fellow at Monash University's Centre for Medicine Use and Safety, within the Monash Institute of Pharmaceutical Sciences (MIPS). Her work focuses on medicine safety and quality use of medicines for older adults. She is particularly interested in the role of healthcare professionals working as knowledge brokers to support the uptake of research evidence and guidelines into clinical practice. Evidence-to-practice gaps are a major barrier to avoiding medication-related harm.…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.